独活寄生汤加减对强直性脊柱炎肾虚督寒证骨代谢和炎症因子的影响

孙鹏; 李建; 沙明波; 陈爽

doi:10.13422/j.cnki.syfjx.2017240202

您当前的位置：

首页 >

文章列表页 >

独活寄生汤加减对强直性脊柱炎肾虚督寒证骨代谢和炎症因子的影响

临床 | 更新时间：2024-01-04

- 独活寄生汤加减对强直性脊柱炎肾虚督寒证骨代谢和炎症因子的影响
- Effect of Addition and Subtraction Treatment of Duhuo Jisheng Tang on Bone Metabolism and Inflammatory Factors of Patients with Ankylosing Spondylitis and Kidney Deficiency
- 中国实验方剂学杂志 2017年23卷第24期页码：202-207
- 作者机构：
- 作者简介：
- 基金信息：
  
  天津市科学技术研究计划项目（2015JQ4014G）
- DOI：10.13422/j.cnki.syfjx.2017240202
  中图分类号： R259
- 纸质出版日期：2017
- 稿件说明：
移动端阅览
孙鹏, 李建, 沙明波, 等. 独活寄生汤加减对强直性脊柱炎肾虚督寒证骨代谢和炎症因子的影响[J]. 中国实验方剂学杂志, 2017,23(24):202-207.

SUN Peng, LI Jian, SHA Ming-bo, et al. Effect of Addition and Subtraction Treatment of Duhuo Jisheng Tang on Bone Metabolism and Inflammatory Factors of Patients with Ankylosing Spondylitis and Kidney Deficiency[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(24): 202-207.
孙鹏, 李建, 沙明波, 等. 独活寄生汤加减对强直性脊柱炎肾虚督寒证骨代谢和炎症因子的影响[J]. 中国实验方剂学杂志, 2017,23(24):202-207. DOI： 10.13422/j.cnki.syfjx.2017240202.

SUN Peng, LI Jian, SHA Ming-bo, et al. Effect of Addition and Subtraction Treatment of Duhuo Jisheng Tang on Bone Metabolism and Inflammatory Factors of Patients with Ankylosing Spondylitis and Kidney Deficiency[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(24): 202-207. DOI： 10.13422/j.cnki.syfjx.2017240202.

摘要

目的：观察独活寄生汤加减治疗强直性脊柱炎（AS）肾虚督寒证的临床疗效及对骨代谢指标和肿瘤坏死因子-α（TNF-α），白细胞介素-6（IL-6）等炎症因子的影响。方法：将120例AS患者随机按数字表法分为对照组和观察组各60例。对照组采用美洛昔康片+柳氮磺胺吡啶片治疗。观察组采用独活寄生汤加减内服。两组疗程均为4个月。评价治疗前后脊柱疼痛视觉模拟评分（VAS），巴氏强直性脊柱炎功能指数（BASFI），炎症病情活动指数（BASDAI），胸廓活动度，腰椎活动度（Schober）试验，枕-墙距、臀-地距、"4"字试验和患者整体评分（PGA）和肾虚督寒证评分等指标；检测治疗前后血沉（ESR），C反应蛋白（CRP），TNF-α，IL-6，降钙素（HCT），甲状旁腺激素（PTH），骨碱性磷酸酶（BALP）和骨钙素（BGP）等指标；进行安全性评价。结果：观察组达到AS疗效评价标准20反应（ASAS20）达标率为70.91%，高于对照组的51.79%（χ2=4.275，P<0.05）；观察组ASAS50达标率为54.54%，高于对照组的19.64%（χ2=14.513，P<0.01）；观察组ASAS70达标率为32.72%，高于对照组的8.93%（χ2=9.566，P<0.01）；观察组BASDAI50达标率为50.91%，高于对照组的16.07%（χ2=15.156，P<0.01）；治疗后观察组患者疼痛VAS，BASFI，BASDAI，PGA，"4"字试验评分均低于对照组，枕-墙距、指-地距均短于对照组，胸廓活动度和腰椎活动度均大于对照组（P<0.05，P<0.01）；观察组肾虚督寒证评分低于对照组（P<0.01）；观察组患者ESR，CRP，TNF-α，IL-6水平均低于对照组（P<0.01）；治疗后两组患者PTH水平均下降（P<0.01），组间PTH水平差异无统计学意义；治疗后观察组患者BGP水平高于对照组（P<0.05）；观察组的不良反应发生情况少于对照组。结论：采用独活寄生汤加减内服治疗AS肾虚督寒证患者能缓解症状，提高运动活动能力，降低疾病活动度，并能下调炎症因子，防止骨量丢失，临床疗效优于对照组，且副作用少。

Abstract

Objective: To observe the clinical efficacy of addition and subtraction treatment of Duhuo Jisheng Tang on ankylosing spondylitis (AS) with kidney deficiency

and investigate its effect on levels of bone metabolism and tumor necrosis factor-α (TNF-α)

interleukin-6 (IL-6) and inflammatory mediators. Method: One hundred and twenty patients with AS were randomly divided into control group (60 cases) and observation group (60 cases) by random number table. Patients in control group got meloxicam tablets and sulfasalazine tablets

and the patients in observation group received addition and subtraction treatment of Duhuo Jisheng Tang. The treatment course was 4 months in both groups. Scores of visual analogue scale (VAS) for spinal pain

bath AS function index (BASFI)

bath ankylosing spondylitis disease activity index (BASDAI)

thoracic activity

lumbar vertebra activity (Schober test)

pillow-wall distance

buttocks-ground distance

"4" figure test and physicians global assessment (PGA)

as well as kidney deficiency scores were evaluated and recorded before and after treatment. Before and after treatment

levels of erythrocyte sedimentation rate (ESR)

C-reactive protein (CRP)

TNF-α

IL-6

human calcitonin (HCT)

parathyroid hormone (PTH)

bone alkaline phosphatase (BALP) and osteocalcin were detected

and safety was evaluated. Result: The compliance rate of assessment in ankylosingspondylitis 20 (ASAS20) was 70.91% in observation group

higher than 51.79% in control group (χ2=4.275

P<0.05). The compliance rate of ASAS50 was 54.54% in observation group

higher than 19.64% in control group (χ2=14.513

P<0.01). The compliance rate of ASAS70 was 32.72% in observation group

higher than 8.93% in control group (χ2=9.566

P<0.01). The compliance rate of BASDAI50 was 50.91% in observation group

higher than 16.07% in control group (χ2=15.156

P<0.01). Scores of VAS of pain

and BASFI

BASDAI

PGA

"4" figure test and physicians global assessment were lower than those in control group

and pillow-wall distance

finger-ground distance were shorter than those in control group

thoracic activity and lumbar activity were larger than those in control group after treatment (P<0.05

P<0.01). Score of kidney deficiency and levels of ESR

CRP

TNF-α

IL-6 in observation group were lower than those in control group (P<0.01). PTH levels were decreased in two groups (P<0.01)

and there was no statistical significance between two groups. Level of BGP in observation group was higher than that in control group (P<0.01). Adverse reactions in observation group were less than those in control group. Conclusion: Addition and subtraction treatment of Duhuo Jisheng Tang can relieve symptoms

improve athletic ability

reduce disease activity

downgrade inflammatory factors and prevent loss of bone mass for ankylosing spondylitis.The clinical efficacy was better than that in western medicine treatment

with less side effects.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

高良姜黄酮组合物抑制PI3K/Akt通路对幽门螺杆菌胃炎小鼠的保护作用

黄芩有效成分治疗骨质疏松症相关信号通路的研究进展

基于JAK2/STAT3通路介导的星形胶质细胞A1/A2表型转化探讨桃红四物汤对脑缺血再灌注损伤的保护作用

五劳七损方调控Wnt/β-catenin信号通路对AS成纤维细胞增殖及成骨分化的影响

骨质疏松症的发病机制及中医药治疗研究进展